Immix Biopharma (IMMX) vs Sana Biotechnology (SANA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Immix Biopharma (IMMX) has outperformed Sana Biotechnology (SANA) over the past year, gaining 265.7% versus a loss of 38.4%. Sana Biotechnology is the larger company by market cap ($842.7 million vs $782.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMMX | SANA |
|---|---|---|
| Share price | $9.44 | $2.82 |
| Market cap | $782.60M | $842.70M |
| 1-day change | +1.61% | +0.90% |
| YTD return | +77.63% | -31.45% |
| 1-year return | +265.75% | -38.41% |
| 5-year return | — | -86.58% |
| EPS (TTM) | $-0.88 | $-0.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.10 | $6.55 |
| 52-week low | $2.31 | $2.61 |
| Distance from 52-week high | -37.48% | -57.02% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +157.42% | +199.47% |
| Average volume | 1.65M | 3.13M |
| Shares outstanding | 82.90M | 299.36M |
| Employees | 21 | 142 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMMX has outperformed SANA by 304.2 percentage points over the past year.
About Immix Biopharma
IMMX stock →Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Sana Biotechnology
SANA stock →Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 142 employees
IMMX vs SANA FAQ
Which is bigger, Immix Biopharma or Sana Biotechnology?
Sana Biotechnology (SANA) is larger, with a market capitalization of $842.70M compared with $782.60M for Immix Biopharma (IMMX).
Which stock has performed better over the past year, IMMX or SANA?
IMMX returned +265.75% over the past 12 months, compared with -38.41% for SANA (price return, excluding dividends). Past performance does not predict future results.
Are Immix Biopharma and Sana Biotechnology in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Immix Biopharma and Biotechnology: Biological Products (No Diagnostic Substances) for Sana Biotechnology.